Literature DB >> 18563364

Investigation of the relationship between in vitro and in vivo release behaviors of acamprosate from enteric-coated tablets.

Yun-Seok Rhee1, Seok Park, Tae-Won Lee, Chun-Woong Park, Tae-Young Nam, Tack-Oon Oh, Ji-Woong Jeon, Dong-Soo Lee, Eun-Seok Park.   

Abstract

Acamprosate calcium is a highly soluble drug with low permeability that is used to maintain abstinence in alcohol-dependent patients. The aim of this study was to investigate the relationship between in vitro and in vivo behaviors of acamprosate from enteric-coated tablets. The in vitro release behavior of acamprosate tablets in pH 6.8 buffer solution was determined in three dissolution conditions, 50 and 150 rpm (paddle method) and 180 rpm (basket method). The results of this in vitro experiment indicated that acamprosate tablets hardly disintegrated, and drug dissolution was retarded despite the extremely hydrophilic nature of the drug. A single dose (333 mgx2 tablets) of each formulation was orally administered to four beagle dogs under fasting conditions, and the pharmacokinetic parameters were calculated. The mean AUC0-48, Cmax, Tlag and Tmax for the two types of tablets ranged from 41.5-53.6 microg.h/mL, 4.3-4.5 microg/mL, 2.0-2.5 h and 3.8-4.0 h, respectively. In conclusion, it is suggested that retarded drug release from the tablets and the low drug permeability may result in poor absorption and erratic bioavailability of this drug in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18563364     DOI: 10.1007/s12272-001-1229-y

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  1 in total

1.  Acamprosate Is a Substrate of the Human Organic Anion Transporter (OAT) 1 without OAT3 Inhibitory Properties: Implications for Renal Acamprosate Secretion and Drug-Drug Interactions.

Authors:  Irina E Antonescu; Maria Karlgren; Maria L Pedersen; Ivailo Simoff; Christel A S Bergström; Sibylle Neuhoff; Per Artursson; Bente Steffansen; Carsten Uhd Nielsen
Journal:  Pharmaceutics       Date:  2020-04-24       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.